LSBC - nine new patents
Kommentaari jätmiseks loo konto või logi sisse
-
19. novembri suurim tõusja oli Large Scale Biology (LSBC) ehk +50%. Huvi pärast vaatasin, et millega tegu ja leidsin alljärgneva info. Kas keegi on selle firma vastu ka ennemalt huvi tundnud ja mida arvata LSBC-st? Äkki eksisteerib pikemas või lühemas perspektiivis võimalus !
Nine Important New Patents Issued to Large Scale Biology Corporation
Boston, MA
November 15, 2001
For immediate release:
BOSTON, Massachusetts, November 15, 2001 -- The U.S. Patent and Trademark Office has issued nine new patents to Large Scale Biology Corporation (Nasdaq: LSBC) with promising product-related implications for the Company's technology platforms in proteomics, functional genomics and biomanufacturing. The new additions bring the Company's total number of U.S. issued patents in these categories to 34.
"As these patents demonstrate, we continue to build a strong patent portfolio to provide a broad proprietary base for all our key technologies and product initiatives," said Robert L. Erwin, Chairman and CEO of LSBC, speaking today at the Stephens, Inc. Healthcare Conference on drug discovery and development technologies. "These new LSBC proprietary patents are important additions to our patent portfolio and demonstrate to potential partners and collaborators the thoroughness of our unique and dominant positions in our specific areas of expertise. The patents are an indication of the quality of our science, and I expect their commercial use is where our shareholders will see the payoff."
Mr. Erwin was joined in the presentation of the new patents by LSBC's newly appointed president, John D. Fowler. An investment banker for 18 years , as well as an attorney ,Mr. Fowler was most recently Managing Director of the Healthcare Group at J.P. Morgan and Company. In explaining his move from banking to the management of the life sciences company, Mr. Fowler cited "the evidence of tremendous under-appreciated value at LSBC with these particular patents providing a good example of why we expect to become known as a product leader beyond being a patents powerhouse."
Erwin and Fowler related the new patents to three key areas for product potential:
Proteomics
U.S. Patent No. 6,254,834 is the first in a series of patents relating to a new technology for distinguishing infectious agents, for identifying known viral pathogens, and for discovering and characterizing unknown viral pathogens. The technology provides rapid detection of viral pathogens, allowing more accurate therapy choices for identified pathogens. "This new technology makes detection of viral pathogens faster and easier, and will permit health officials to track the spread of viral diseases in real time," said Erwin. "This novel technology has the capacity to usher in a new era of viral pathogen detection and identification. The product of many years of research and development, the timing of this patent could not be more timely for public health concerns."
Mr. Fowler added, "Expanding our rights in the area of viral detection enables us to develop new means of identifying and tracking infections earlier, with important public health safety implications, as well as potential savings for the public and private medical care system."
LSBC was also awarded two key patents (U.S. Patents No. 6,301,377 and 6,298,874) that protect critical aspects of its proprietary automated 2-D gel electrophoresis systems (ProGEx™), including 2-D gel image analysis, automated gel staining, and gel manipulation. "These patents further strengthen LSBC's leadership in industrial proteomics ," said Mr. Fowler. "Potential commercial applications of our proteomics capabilities are being demonstrated now in landmark alliances and research collaborations with the Stanley Foundation Research Programs, Stanford University and the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida. The commercial development of these capabilities continues to be an area of focused concentration." Mr. Fowler credited LSBC's chief scientist, Norman G. Anderson, Ph.D., and the Company's chief scientific officer N. Leigh Anderson, Ph.D., with "attracting and developing the most distinguished assemblage of proteomics scientists in the world" at its Germantown, Maryland laboratories.
Genomics
U.S. Patent No. 6,303,848 covers the ability of the Company's core GENEWARE® transient expression system to protect a crop from an herbicide that is intended to kill weeds. Because GENEWARE affects only the current plant generation and does not genetically modify seeds, crops like corn and soybeans would not transmit the foreign gene to subsequent generations. This technology therefore allows an alternative to GMO foods, and other GMO products. "As we explore potential domestic and global collaborations in agriculture, this patent will add even more of an attraction to our product technologies," Mr. Fowler said. "We have already demonstrated the ability of our system to manufacture biotechnology and pharmaceutical products at our Owensboro, Kentucky facility For example , we utilize viral vectors in tobacco plants to produce human protein for our non-Hodgkin's lymphoma vaccine currently in clinical trials."
Biomanufacturing
U.S. Patents No. 6,284,875 and 6,303,779 are important additions to the part of the intellectual property portfolio that protects LSBC's biomanufacturing process to extract valuable biomolecules. Specifically, these patents protect a process for extracting sugars from plants, and for recovering pharmaceutical proteins from plant tissues. Additionally, U.S. Patents No. 6,284,492; 6,300,133; and 6,300,134 are directed to both plant and animal viral vectors. "These patents protect LSBC's proprietary biomanufacturing and extraction technologies," said Mr. Erwin. We believe these processes will permit alternative and more cost-effective manufacturing platforms for a variety of therapeutic protein products, as well as the ability to respond rapidly to viral threats with new vaccines."
About Large Scale Biology Corporation
Large Scale Biology uses its proteomics, functional genomics and biomanufacturing technologies to develop and manufacture personalized drugs, vaccines and diagnostics for rapid identification and effective treatment of disease. Corporate offices and the Genomics operations are headquartered in Vacaville, California; the Company's Proteomics operations are located in Germantown, Maryland; and the Company's bioprocessing and manufacturing facilities are located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current plans, expectations, estimates, and projections and management's beliefs about our future performance. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities Exchange Commission. Unless required by law, Large Scale Biology Corporation undertakes no obligation to update publicly any forward-looking statements.
GENEWARE® and ProGEx™ are trademarks of Large Scale Biology Corporation.
